We are at #AACR2023 today presenting our large scale integration and analysis of scRNA-seq data related to #immunotherapy response
LB176: Interrogating the single cell immune checkpoint inhibition atlas to decipher ICI response mechanisms
abstractsonline.com/pp8/#!/1…
Janusz Dutkowski is speaking at #PMWC23 on January 27 at the Santa Clara Convention Center. He will be discussing exciting updates to Data4Cure's Biomedical Intelligence Cloud and its Knowledge Graph Ecosystem #knowledgegraphs#translationalresearch#drugdiscovery.
Thank you to the speakers in our session: Pallavi Sachdev @PSachdev0802 and Paul Rejto and thanks to Tal Bahar and @PMWCintl team for a great conference!
Janusz Dutkowski, PhD, Co-founder & CEO, Data4Cure, will be joined by Pallavi Sachdev, MPH, PhD, Director, Oncology Biomarker Research, @Eisai, and Paul Rejto, PhD, VP, Oncology Translational Research, @Pfizer.
A critical step forward in the battle against breast cancer. The first cancer immunotherapy regimen approved- specifically in the patients whom benefit most. But breast cancer is a immunologically complex disease- and more advances are needed to help the rest. #immunotherapy
FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative #breastcancer. #bcsm Drug label: go.usa.gov/xEGzx
@jdutkowski@Data4Cure platform uses #AI / #MachineLearning approach to identify model of response in IMvigor210 that combines genomic, pathologic, and clinical features. Identifies Wnt signaling pathway as feature, would’ve been missed in univariate analysis #PMWC19#PMWC2019
BREAKING NEWS
The 2018 #NobelPrize in Physiology or Medicine has been awarded jointly to James P. Allison and Tasuku Honjo “for their discovery of cancer therapy by inhibition of negative immune regulation.”
Data4Cure's @jdutkowski discussing the CURIE Knowledge Graph integrating evidence from millions of datasets and publications to inform patient stratification and target and biomarker discovery. Today at #PrecisionBiomarkersSummit Munich bit.ly/2p1IdLM